Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
DISASTERS AVERTED — Near Miss Case Studies
Preventing Potential Drug Interaction with a Drug With UNIQUE Directions
TOP STORIES — Diabetes News and Research
Gender Affects Vascular Disease Associated with Diabetes
How Do Patients Prefer to Take their Insulin and Monitor Blood Glucose?
Can Exenatide Improve Glycemic Control In Type 1 Diabetes?
MOST POPULAR ARTICLES OF THE MONTH
#1 A1C levels are Indicators of Coronary Atherosclerotic Plaque Formation
#2 Renal Disease Impact On Long-Term Metformin Use
#3 Did You Know? Metformin, along with dozens of drugs, may have promise against COVID-19
Modern technology has made glucose management much easier for all patients and especially those using insulin. Although we typically think that everyone will like all the data and management tools CGM and pump technology offer, there can be an overload of information that creates undue stress for the patient.
This week in a special feature from our intern Jordan Boyd, PharmD. Candidate Florida Agricultural & Mechanical University School of Pharmacy, we focus on why some patients love the technology and why some don’t, and why it is important to find out how each individual patient feels.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
DISASTERS AVERTED — Near Miss Case Studies
We were following up with a person with type 2 diabetes who was recently started on the new oral formulation of the GLP-1 receptor agonists semaglutide (Rybelsus®). This patient had a 12-year history of type 2 diabetes as well as several comorbidities that included hypertension, hyperlipidemia, obesity (BMI = 33 kg/m2), knee osteoarthritis, and hypothyroidism. The patient was previously resistant to initiating a GLP-1 receptor agonist due to his hesitancy toward self-injection. He agreed at his last primary care visit to start a trial of oral semaglutide to improve his glucose control and lose some weight….
TOP STORIES — Diabetes News and Research
How adipose tissue storage, which differs by gender, plays a role in the development and treatment of the disease.
Are patients on board with new insulin delivery and glucose monitoring technology?
The MAG1C interventional study was a single-center, 26-week, phase 2a, to look at how Exenatide might benefit patients with type 1 diabetes.